MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin

World Journal of Gastroenterology

Volumn 20, Issue 32, 2014, Pages 11347-11355

  Zhang, Xiang Liang ^a   Shi, Hui Juan ^b   Wang, Ji Ping ^c   Tang, Hong Sheng ^a   Wu, Yin Bing ^a   Fang, Zhi Yuan ^a   Cui, Shu Zhong ^a   Wang, Lian Tang ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Advanced gastric cancer; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; MicroRNA; MiR 218; Multi drug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; MICRORNA; MICRORNA 218; RAPAMYCIN; UNCLASSIFIED DRUG; MIRN218 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ANESTHESIST; ARTICLE; CANCER CHEMOTHERAPY; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLONY FORMATION; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICAL ETHICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STABLE EXPRESSION; STOMACH CANCER; UPREGULATION; ADJUVANT CHEMOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL SURVIVAL; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GASTRECTOMY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HYPERTHERMIC THERAPY; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PERFUSION; PROCEDURES; STOMACH NEOPLASMS; TIME; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYTOREDUCTION SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRECTOMY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERTHERMIA, INDUCED; INHIBITORY CONCENTRATION 50; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERFUSION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84909619380     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i32.11347     Document Type: Article

References (39)

1. Shim JH, Ko KJ, Yoo HM, Oh SI, Jeon DJ, Jeon HM, Park CH, Song KY. Morbidity and mortality after non-curative gastrectomy for gastric cancer in elderly patients. J Surg Oncol 2012; 106: 753-756 [PMID: 22495554 DOI: 10.1002/jso.23121]
2. Zhang XL, Shi HJ, Cui SZ, Tang YQ, Ba MC. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol 2011; 37: 466-472 [PMID: 21414740 DOI: 10.1016/j.ejso.2011.01.027]
3. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Franc¸ois Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363 [PMID: 10640968]
4. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011; 104: 692-698 [PMID: 21713780 DOI: 10.1002/jso.22017]
5. Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol 2012; 106: 197-203 [PMID: 22331814 DOI: 10.1002/jso.23062]
6. Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, Gilly FN. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 2007; 31: 1813-1820 [PMID: 17629740 DOI: 10.1007/s00268-007-9146-8]
7. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010; 17: 2370-2377 [PMID: 20336386 DOI: 10.1245/s10434-010-1039-7]
8. Helm CW, Randall-Whitis L, Martin RS, Metzinger DS, Gordinier ME, Parker LP, Edwards RP. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 2007; 105: 90-96 [PMID: 17173957 DOI: 10.1016/j.ygyno.2006.10.051]
9. Ba MC, Cui SZ, Lin SQ, Tang YQ, Wu YB, Wang B, Zhang XL. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol 2010; 16: 1901-1907 [PMID: 20397270 DOI: 10.3748/wjg.v16.i15.1901]
10. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005; 92: 370-375 [PMID: 15739249 DOI: 10.1002/bjs.4695]
11. Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Franc¸ois Y, Vignal J, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004; 139: 20-26 [PMID: 14718269 DOI: 10.1001/archsurg.139.1.20]
12. Mori T, Fujiwara Y, Sugita Y, Azama T, Ishii T, Taniguchi K, Yamazaki K, Takiguchi S, Yasuda T, Yano M, Monden M. Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma. Ann Surg Oncol 2004; 11: 14-20 [PMID: 14699028 DOI: 10.1007/BF02524340]
13. Scaringi S, Kianmanesh R, Sabate JM, Facchiano E, Jouet P, Coffin B, Parmentier G, Hay JM, Flamant Y, Msika S. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol 2008; 34: 1246-1252 [PMID: 18222622 DOI: 10.1016/j.ejso.2007.12.003]
14. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, Sumida M, Ohkubo H. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997; 79: 884-891 [PMID: 9041149]
15. Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, Geisinger KR, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004; 8: 454-463 [PMID: 15120371 DOI: 10.1016/j.gassur.2003.12.014]
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297 [PMID: 14744438 DOI: 10.1016/S0092-8674(04)00045-5]
17. Claverie JM. Fewer genes, more noncoding RNA. Science 2005; 309: 1529-1530 [PMID: 16141064 DOI: 10.1126/science.1116800]
18. Hui C, Yujie F, Lijia Y, Long Y, Hongxia X, Yong Z, Jundong Z, Qianyong Z, Mantian M. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. Breast Cancer Res 2012; 14: R80 [PMID: 22616882 DOI: 10.1186/bcr3194]
19. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 2012; 14: R77 [PMID: 22583478 DOI: 10.1186/bcr3187]
20. Nilsson S, Möller C, Jirström K, Lee A, Busch S, Lamb R, Landberg G. Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One 2012; 7: e36051 [PMID: 22563438 DOI: 10.1371/journal.pone.0036051]
21. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, Oliveira C. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol 2012; 228: 31-44 [PMID: 22450781]
22. He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, Xu HC, Xu X, Tang D, Zheng XF, Xue YP, Huang GC, Sun WH. Downregulation of miR-101 in gastric cancer correlates with cyclo-oxygenase-2 overexpression and tumor growth. FEBS J 2012; 279: 4201-4212 [PMID: 23013439 DOI: 10.1111/febs.12013]
23. Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F, Hackermüller J. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013; 32: 277-285 [PMID: 22391564 DOI: 10.1038/onc.2012.55]
24. Li T, Li RS, Li YH, Zhong S, Chen YY, Zhang CM, Hu MM, Shen ZJ. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 2012; 187: 1466-1472 [PMID: 22341810 DOI: 10.1016/j.juro.2011.11.082]
25. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 2009; 106: 1814-1819 [PMID: 19188590 DOI: 10.1073/pnas.0808263106]
26. Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O, Sitbon E, Lithwick Yanai G, Elyakim E, Cholakh H, Gibori H, Spector Y, Bentwich Z, Barshack I, Rosenfeld N. MiR-92b and miR-9/9∗ are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 2009; 19: 375-383 [PMID: 18624795 DOI: 10.1111/j.1750-3639.2008.00184.x]
27. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12 [PMID: 16989803 DOI: 10.1016/j.ydbio.2006.08.028]
28. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004 [PMID: 14973191 DOI: 10.1073/pnas.0307323101]
29. Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Tumori 2001; 87: S3-S5 [PMID: 11693816 DOI: 10.1053/ejso.2000.1038]
30. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004; 5: 219-228 [PMID: 15050953 DOI: 10.1016/S1470-2045(04)01425-1]
31. Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, Li N, Tang B, Liu KY, Xiao B. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012; 7: e41629 [PMID: 22860003 DOI: 10.1371/journal.pone.0041629]
32. Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Arimizu N. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988; 208: 36-41 [PMID: 3133994 DOI: 10.1097/00000658-198807000-00005]
33. Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007; 14: 2702-2713 [PMID: 17653801 DOI: 10.1245/s10434-007-9487-4]
34. Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003; 21: 233-248 [PMID: 14648781 DOI: 10.1002/ssu.10042]
35. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, Nie Y, Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 2010; 6: e1000879 [PMID: 20300657 DOI: 10.1371/journal.pgen.1000879]
36. Gao C, Zhang Z, Liu W, Xiao S, Gu W, Lu H. Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer 2010; 116: 41-49 [PMID: 19890957]
37. Emoto S, Yamaguchi H, Kamei T, Ishigami H, Suhara T, Suzuki Y, Ito T, Kitayama J, Watanabe T. Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surg Today 2014; 44: 919-926 [PMID: 23887848]
38. Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer 2013; 49: 3616-3624 [PMID: 23899532 DOI: 10.1016/j.ejca.2013.07.003]
39. Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver 2013; 7: 385-393 [PMID: 23898376 DOI: 10.5009/gnl.2013.7.4.385]